Skip to content
Programs

From allosteric mechanisms to selective medicines

Advancing programs in neurodegeneration and expanding into therapeutic areas including oncology and pain. We focus on targets where dynamic regulation and selectivity create opportunities for differentiated therapeutic intervention.

Our approach

Advancing focused therapeutic programs

AllotarX™ accelerates the identification and refinement of therapeutic candidates by integrating physics-based, AI-driven approaches with closed-loop learning.

High-Impact Targets

We focus on targets governed by dynamic regulatory mechanisms, where traditional structure-based approaches have struggled and allosteric control can create new intervention opportunities.

New Interventions

Working from conformational ensembles, we uncover allosteric mechanisms, including transient regulatory sites and states, that static structural models do not reveal.

Selective Candidates

We design and optimize selective modulators, refining candidates against related proteins through experimental feedback and closed-loop learning.

Programs

Our programs

Each program advances from Site & Selectivity Design through Hit Discovery & Validation and Lead Optimization to Development Candidate.

Alzheimer’s disease

Selective allosteric modulation of APH1B-containing γ‑secretase to reshape amyloid-β processing.

NIH SBIR Phase I
Powered by AllotarX™
Site & Selectivity DesignHit Discovery & ValidationLead OptimizationDevelopment Candidate
Selective candidates prioritized for validation

GLP-1 receptor (neurodegeneration)

CNS-targeted allosteric modulation of GLP-1R to enhance endogenous receptor signaling.

Internal
Powered by AllotarX™
Site & Selectivity DesignHit Discovery & ValidationLead OptimizationDevelopment Candidate
Allosteric design & prioritization underway
Strategy

Asset-centric strategy

Programs are advanced toward value-creating milestones and strategic partnering opportunities.

Partnering

Partnership potential

Program design supports future co-development, licensing, and pharma collaboration pathways.

Growth

Expansion

Beyond our lead programs, we are running early-stage discovery on additional targets in rare diseases, with oncology and pain as future growth areas.

Drug the undruggable: discover how AllotarX™ is advancing precision allosteric programs